Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Net Cash Flow (2016 - 2026)

Pharma-Bio Serv's Net Cash Flow history spans 17 years, with the latest figure at $2.4 million for Q1 2026.

  • For Q1 2026, Net Cash Flow rose 324.96% year-over-year to $2.4 million; the TTM value through Jan 2026 reached -$1.6 million, down 271.53%, while the annual FY2025 figure was -$3.4 million, 6.24% up from the prior year.
  • Net Cash Flow reached $2.4 million in Q1 2026 per PBSV's latest filing, up from -$586201.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $7.6 million in Q4 2023 to a low of -$7.3 million in Q1 2023.
  • Average Net Cash Flow over 5 years is -$691748.4, with a median of $245575.0 recorded in 2022.
  • The largest YoY upside for Net Cash Flow was 3008.91% in 2023 against a maximum downside of 577.36% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $245575.0 in 2022, then soared by 3008.91% to $7.6 million in 2023, then crashed by 96.73% to $249957.0 in 2024, then plummeted by 334.52% to -$586201.0 in 2025, then soared by 505.14% to $2.4 million in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Net Cash Flow are $2.4 million (Q1 2026), -$586201.0 (Q4 2025), and $1.9 million (Q3 2025).